Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 3/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17265646 | 0.87 | MAPT (0.52) | LGMNMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL29710195 | 0.86 | LGMN (0.62) | LGMNMAPTALOX15SMN1; SMN2NPC1 | |
| SCHEMBL2087889 | 0.86 | LGMN (0.62) | LGMNMAPTALOX15SMN1; SMN2NPC1 | |
| SCHEMBL3376365 | 0.83 | ALDH1A1 (0.56) | LGMNMAPTALOX15SMN1; SMN2NPC1 | |
| SCHEMBL22289269 | 0.83 | ALDH1A1 (0.61) | LGMNMAPTALOX15NPC1RAB9A | |
| SCHEMBL904452 | 0.83 | LGMN (0.73) | LGMNMAPTALOX15SMN1; SMN2NPC1 | |
| SCHEMBL1127082 | 0.81 | ALDH1A1 (0.65) | LGMNMAPTALOX15NPC1RAB9A | |
| SCHEMBL22716931 | 0.80 | LGMN (1.00) | LGMNMAPTALOX15SMN1; SMN2NPC1 | |
| SCHEMBL2376896 | 0.79 | LGMN (0.49) | LGMNMAPTALOX15SMN1; SMN2NPC1 | |
| SCHEMBL17742335 | 0.79 | LGMN (0.67) | LGMNMAPTALOX15SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656249-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | HANMI PHARM. CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| CN-113365996-B | Imidazole pyridine derivative compound and pharmaceutical composition | 韩美药品株式会社 | 2024-09-03 | — | — | CN | disclosed |
| EP-3478687-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2024-03-20 | — | — | EP | disclosed |
| EP-4327884-A2 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | Origenis GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| CN-111217816-B | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-08-16 | — | — | CN | disclosed |
| US-20220098205-A1 | IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME | HANMI PHARM. CO., LTD. (KR) | 2022-03-31 | — | — | US | disclosed |
| EP-3950691-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-10 | — | — | US | disclosed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| US-6339099-B1 | FOR THERAPY AND PROPHYLAXIS OF THROMBOEMBOLIC DISORDER | DUPONT PHARMACEUTICALS COMPANY | 2002-01-15 | — | — | US | disclosed |
| EP-0991638-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-04-12 | — | — | EP | disclosed |
| CN-1246847-A | Nitrogen containing heteroaromatics as factor Xa inhibitors | DU PONT MERCK PHARMA (US) | 2000-03-08 | — | — | CN | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998057951-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098205-A1 | IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME | KDM1A, KDM1B, KDM2A | LGMN 2604/4885PLK4 1463/4885MAPT 251/4885 |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | TFPI, F11, F12 | LGMN 557/4885PLK4 4054/4885MAPT 4607/4885 |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | KDM1A, KDM1B, KDM2A | LGMN 2604/4885PLK4 1463/4885MAPT 251/4885 |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | F11, SERPINC1, TFPI | LGMN 384/4885PLK4 4034/4885MAPT 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.